| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Kanamycin sulfate, the sulfate salt of Kanamycin (Kanamycin A; Kantrex; Kanamycine), is an aminoglycoside bacteriocidal antibiotic effective against gram-positive and negative bacteria and mycoplasma. It has been used for the prevention and treatment of chicken pullorum, colibacillosis, enteritis and other diseases, and has a significant effect on systemic sepsis, respiratory tract infection, peritonitis, etc. caused by drug-resistant bacteria.Aminoglycosides like kanamycin irreversibly bind to specific 30S-subunit proteins and 16S rRNA. Specifically Kanamycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12.
| ln Vitro |
In vitro, different strains of mycobacteria show good antibacterial activity (MIC=1–5 μg/mL) when treated with kanamycin sulfate (0.1–100 μg/mL; 2 weeks)[1].
|
|---|---|
| ln Vivo |
In the lung and spleen of mice, kanamycin sulfate (2, 4 mg/kg; s.c.; once daily, six times a week for three weeks) inhibits the growth of bovine tubercle bacilli[1].
Kanamycin sulfate (1.25, 5 mg/kg; s.c.; single (at 3 h after infection)) increases the survival rate of mice while also inhibiting the growth of K. pneumonia DT-S in the lung, trachea, and blood of the mice in proportion to the dose administration[2]. |
| Cell Assay |
Cell Line: mycobacteria Ravenel, Kirchbergand, H37Rv, H2, and BCG.
Concentration: 0.1-100 μg/mL Incubation Time: 2 weeks Result: demonstrated strong antibacterial activity against multiple mycobacterium strains (H37Rv, H2, H37RvR-PAS, Ravenel, and BCG), with MICs of 1 μg/mL and 5 μg/mL for the Kirchbergand strain, respectively. |
| Animal Protocol |
Animal Model: Model of infected bovine tubercle bacilli (Ravenel strain) in inbred strain normal mice (14–16 g)[1].
Dosage: 2, 4 mg/kg Administration: Subcutaneous injection; once daily, 6 times a week for 3 weeks. Result: demonstrated a notable impact on preventing the in vivo spread of tuberculosis, particularly in mouse lungs. |
| References |
|
| Molecular Formula |
C18H38N4O15S
|
|---|---|
| Molecular Weight |
582.575
|
| Exact Mass |
582.2054
|
| Elemental Analysis |
C, 37.11; H, 6.57; N, 9.62; O, 41.19; S, 5.50
|
| CAS # |
25389-94-0
|
| Related CAS # |
Kanamycin;59-01-8
|
| Appearance |
Solid powder
|
| SMILES |
S(=O)(=O)(O[H])O[H].O([C@]1([H])[C@@]([H])([C@]([H])([C@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])N([H])[H])O[H])[C@@]1([H])[C@@]([H])(C([H])([H])[C@@]([H])([C@]([H])([C@@]1([H])O[H])O[C@]1([H])[C@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])O[H])N([H])[H])N([H])[H]
|
| InChi Key |
OOYGSFOGFJDDHP-KMCOLRRFSA-N
|
| InChi Code |
InChI=1S/C18H36N4O11.H2O4S/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17;1-5(2,3)4/h4-18,23-29H,1-3,19-22H2;(H2,1,2,3,4)/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-;/m1./s1
|
| Chemical Name |
(2R,3S,4S,5R,6R)-2-(aminomethyl)-6-(((1R,2R,3S,4R,6S)-4,6-diamino-3-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4,5-triol sulfate
|
| Synonyms |
Kanamycin sulfate; kanamycin A. Kanabristol; Kanacedin.
|
| HS Tariff Code |
2941.90.1010
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 25 mg/mL (~42.91 mM)
DMSO : < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (85.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: 50 mg/mL (85.83 mM) in Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7165 mL | 8.5825 mL | 17.1650 mL | |
| 5 mM | 0.3433 mL | 1.7165 mL | 3.4330 mL | |
| 10 mM | 0.1717 mL | 0.8583 mL | 1.7165 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
